Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YHR2402
- Development stage
- Phase 1
- Lead developer
- Yuhan
01
Overview
YHR2402 is an investigational drug developed by Yuhan Corp. It is currently in Phase 1 clinical trials, primarily being studied for its pharmacokinetic profile and safety in healthy volunteers. The specific mechanism of action, molecular target(s), modality, and therapeutic area have not been publicly disclosed as of the latest available data. There are no approved indications or known adverse events reported for this compound to date[1][3]. The drug has also been evaluated in combination with another investigational agent, YHR2403, to assess potential pharmacokinetic interactions[2][4].
- Other names
- YHR-2402YHR2402YHR 2402
Beyond the preview
Go deeper on YHR2402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YHR2402.